[{"Assets_0_Q3_USD":379085000.0,"CommonStockSharesOutstanding_0_Q3_shares":19360000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":879000.0,"NetIncomeLoss_1_Q3_USD":20288000.0,"NetIncomeLoss_3_Q3_USD":44536000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":21017000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":20509000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":19303000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":19212000.0,"StockholdersEquity_0_Q3_USD":360901000.0,"EarningsPerShareBasic_1_Q3_USD":1.05,"EarningsPerShareBasic_3_Q3_USD":2.32,"EarningsPerShareDiluted_1_Q3_USD":0.97,"EarningsPerShareDiluted_3_Q3_USD":2.17,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":57262000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":139420000.0,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180809"}]